Document:

Exhibit 10.7

 

Agreement No. A19363

  

EXCLUSIVE OPTION AGREEMENT

Agreement No. A19363

 

TABLE OF CONTENTS

 

	 	Section	1	Grant
	 	Section	2	Option Period
	 	Section	3	Diligent Efforts
	 	Section	4	Sharing of Information
	 	Section	5	Option Fee
	 	Section	6	Patent Costs
	 	Section	7	Payments
	 	Section	8	No Warranties
	 	Section	9	No Assignment
	 	Section	10	Indemnification; Insurance
	 	Section	11	Termination
	 	Section	12	Use of Names
	 	Section	13	United States Government Interests
	 	Section	14	Miscellaneous
	 	Section	15	Notices and Other Communications
	 	Section	16	Force Majeure
	 	Section	17	Integration
	 	Section	18	Contract Formation and Authority

 

This Agreement is effective
as of the date of the last signature below, (the “Effective Date”), between the University of Florida Research Foundation,
Incorporated (hereinafter called “UFRF”), a nonstock, nonprofit Florida corporation, and Signet International Holdings,
Inc., (hereinafter called “COMPANY”), a small entity Florida Corporation having its principal office at 205 Worth Avenue,
Suite #316, Palm Beach, FL 33480.

 

WHEREAS, UFRF is the
owner of certain Patent Rights relating to UF Technology No. T14638, U.S. Patent Application Serial No. 15/479,078, entitled
Methods and Systems for detecting Melanoma, invented by Nikolaus Gravenstein, Christiana Shaw, Michael Costanzo, Ricky Yost, Candice Ulmer,
Louis Seary (hereinafter “Patent Rights”);

 

 

    Page 1 of 11

     

    

 

Agreement No. Al 9363

 

WHEREAS, UFRF desires to transfer this technology to benefit the public;

 

WHEREAS, UFRF and COMPANY recognize
that further work is required to develop to practical application the invention that is described and claimed in the Patent Rights;
and

 

WHEREAS, COMPANY desires a period
of time in which to evaluate the Patent Rights, potential products, and markets therefor, and to elect to negotiate a license for
such Patent Rights.

 

THEREFORE, in consideration
of the premises and mutual covenants contained herein, the parties hereto agree as follows:

 

Section l Grant

 

UFRF hereby grants to COMPANY
an exclusive Option to negotiate a royalty-bearing, limited-term, exclusive license to the Patent Rights in the following field(s)
of use: cancer such as melanoma and other cancers for the territory of worldwide (hereinafter the “Option Rights”).
During the Option Period (defined below), COMPANY shall have the right to use the Patent Rights only to evaluate Option Rights
according to the Evaluation Plan in Exhibit A (the “Evaluation Plan”).

 

Section 2
Option Period

 

The Option Period shall
commence on the Effective Date and expire on August 31, 2020, unless sooner terminated by the
execution of a license agreement between the parties for the Option Rights. If COMPANY
shall exercise its option hereunder by written
notice to UFRF within the Option Period, the parties shall negotiate the license terms in good faith. However, all Option
Rights expire on the later of ninety (90) days following UFRF’s receipt of such written
notice by COMPANY exercising its Option Rights, or the last day of the Option Period.

 

Section 3 Diligent
Efforts

 

During the Option Period,
COMPANY shall use diligent efforts to evaluate the inventions described and claimed in the Patent Rights. Such efforts shall include,
but shall not be limited to, the sponsoring or performing work defined in the Evaluation Plan (Exhibit A) and the sharing of information
regarding the results of the Evaluation Plan with UFRF. COMPANY shall submit to UFRF the Evaluation Report with relevant documentation
no later than ten (10) business days prior to the expiration of the Option Period.

 

 

    Page 2 of 11

     

    

 

Agreement No. A19363

  

Section 4
Sharing of Information

 

During the Option Period, COMPANY,
UFRF and University of Florida shall share information obtained during or necessary for the conduct of the Evaluation Plan. Such
information shall be exchanged under the terms of a Mutual Confidential Disclosure Agreement (Exhibit B). If
a new invention whether patentable or not results from the sharing of information, COMPANY shall promptly provide notice of such
invention to UFRF within thirty (30) days of such invention so that COMPANY and UFRF can come to an agreement on the filing of
any patent applications using an attorney of UFRF’s choice. If
the COMPANY does not exercise its option under this Agreement or a license agreement is not executed between the parties,
COMPANY will be obligated to deliver to UFRF no later than ninety (90) days after termination of the Option Period any data that
are generated by COMPANY under this Agreement. UFRF shall own such data. In addition, if a license agreement is not executed between
the parties within the timeline stated in Section 2 above, COMPANY shall assign to UFRF any rights to inventions made during this
Option Period, and COMPANY shall keep all information disclosed by UFRF or generated by either party under this Agreement confidential
per the provisions of the executed Confidentiality Disclosure Agreement. COMPANY shall not use such data or information for any
purpose. COMPANY warrants that all its employees and agents are obligated to assign to COMPANY all their rights in data, information,
and inventions made during the Option Period.

 

Section 5
Option Fee

 

In consideration of the Option
Rights herein granted to COMPANY by UFRF and as an indication of serious intent, COMPANY shall pay to UFRF the sum of one thousand
two hundred dollars ($1,200) within thirty (30) days of the Execution Date, such sum to be nonrefundable.

 

Section 6 Patent Costs

 

UFRF will solicit input
from COMPANY regarding (a) actions to be taken in connection with patent protection for the Patent Rights, and (b) fees,
annuities, costs and expenses to be incurred in connection therewith. UFRF will submit, or will cause to be submitted to
COMPANY all correspondence or other materials related to the preparation, filing, prosecution (including interferences and
oppositions), issuance, maintenance and reporting of the Patent Rights for COMPANY’s review and comment prior to any filing
or other submission thereof, and UFRF will give due consideration to comments provided by COMPANY or COMPANY’s counsel. If COMPANY
fails to provide comments regarding actions to be taken, submissions or payment of fees, annuities, or other costs or
expenses within fourteen (14) days of the date of UFRF’s submission thereof to COMPANY, then UFRF will assume COMPANY has no
comments. During the Option Period, COMPANY shall reimburse UFRF for United States and/or foreign costs associated with the
Patent Rights. If COMPANY shall not exercise its Option Rights, COMPANY shall in any event be liable to UFRF for UFRF’s
out-of-pocket United States and foreign filing, prosecution, and maintenance costs, including attorneys’ fees, in countries
selected by COMPANY and incurred during the Option Period or any ensuing period of good faith negotiations as set forth in
Section 2 above. Such costs shall be reimbursed by COMPANY within thirty (30) days of invoicing by UFRF. COMPANY shall pay
all amounts owing to UFRF under this Agreement in United States dollars at the following address:

 

University of Florida Research
Foundation, Inc.

288 Grinter Hall, PO Box 115500

Gainesville, Florida 32611-5500

Attention: Business Manager

 

 

  

    Page 3 of 11

     

    

 

Agreement No. A19363

 

For Wire Transfer Information: http://research.ufl.edu/ufrf/wiring.html.
The wire transfer link is also included at the bottom of all invoices for your accounting purposes.

 

Section 7
Payments

 

Any amounts which remain unpaid
after the date they are due to UFRF under any section of this Agreement shall accrue interest from the due date at the rate of
one and one-half percent (1.5%) per month. However, in no event shall this interest provision be construed as a grant of permission
for any payment delays. COMPANY is responsible for all wire/bank fees associated with all payments due to UFRF pursuant to this
Agreement. COMPANY shall also be responsible for repayment to UFRF of any attorney, collection
agency, or other out-of-pocket UFRF expenses required to collect overdue payments due from any applicable section of this Agreement

 

Section 8 No Warranties

 

EXCEPT AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, UFRF MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING
BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED
OR PENDING.

 

Section 9 No Assignment

 

The Option Agreement and the
Option Rights shall not be assignable, whether by operation of law or otherwise, and any attempt to do so shall be
void.

 

 

 

    Page 4 of 11

     

    

 

Agreement No. A19363

 

Section 10 lndemnification;
Insurance

 

	10.1	COMPANY shall, at all times during the term of this Agreement
and thereafter, indemnify, defend and hold UFRF, the University of Florida Board of Trustees, the University of Florida, and each
of their directors, officers, employees, and agents, and the inventors of the Patent Rights, regardless of whether the inventors
are employed by the University of Florida at the time of the claim, harmless against all claims and liabilities, including legal
expenses and reasonable attorneys’ fees, whether arising from a third party claim or resulting from UFRF’s enforcing this
indemnification clause against COMPANY, arising out of the death of or injury to any person or persons or out of any damage to
property and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from COMPANY’s
evaluating the Patent Rights or any other use of Patent Rights by COMPANY. Notwithstanding the above, UFRF at all times reserves
the right to retain counsel of its own to defend the interests of UFRF, the Florida Board of Governors, the University of Florida
Board of Trustees, the University of Florida and the inventors of the Patent Rights.

 

	10.2	COMPANY warrants that it will maintain liability insurance
coverage appropriate to the risk involved in evaluating the Patent Rights.

 

Section 11 Termination

 

	11.1	UFRF may terminate this Agreement by giving COMPANY
at least thirty (30) days written notice if COMPANY:

 

		11.1.1	is delinquent on any report or payment obligation
under this Agreement;

 

		11.1.2	is not diligently developing the Patent Rights or
meeting the milestones as outlined in the Evaluation Plan;

 

		11.1.3	is in breach of any provision of this Agreement;

 

		11.1.4	provides any false report to UFRF;

 

		11.1.5	goes into bankruptcy, liquidation, or proposes having
a receiver assume control any of its assets;

 

		11.1.6	violates any laws or regulations of applicable government
entities; or

 

		11.1.7	ceases to carry on its business pertaining to the
Patent Rights

 

	11.2	Termination under this
Section 11 will take effect 30 days after written notice by UFRF unless COMPANY remedies the problem in that 30-day period. COMPANY
may terminate this Agreement at any time by providing UFRF at least 45 days written notice. Upon the termination of this
Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to
the effective date of such termination.

 

 

 

    Page 5 of 11

     

    

 

Agreement No. A19363

 

Section 12 Use of Names

 

COMPANY may not use the names
or logos of UFRF or the University of Florida, nor of any of either institution’s employees, agents, or affiliates, nor the name
of any inventor of Patent Rights, nor any adaptation of those names, in any promotional, advertising or marketing materials or
any other form of publicity, or to suggest any endorsement by these entities or individuals, without the prior written approval
of UFRF in each case.

 

Section 13 United
States Government Interests

 

The United States Government
has funded Grant No. – N/A - during the course of or under
which any of the inventions of the Patent Rights were conceived or reduced to practice. The United States Government is entitled
under the provisions of 35 U.S.C. §202-212 and applicable regulations to a non-exclusive, nontransferable, irrevocable, paid-up
license to practice or have practiced those inventions for or on behalf of the United States throughout the world. Any license
granted to COMPANY in this Agreement is subject to that license.

 

Section 14 Miscellaneous

 

	 	14.1	Governing Law. This Agreement shall be governed
and construed in accordance with the internal laws of the State of Florida without regard to its conflict of laws provisions,
and venue for all claims or other causes of action arising out of this Agreement shall be in Gainesville, Florida. If any provisions
of this Agreement are held invalid or unenforceable by a court of competent jurisdiction, those provisions shall be deemed automatically
deleted; the remaining terms and conditions of this Agreement shall remain in full force and effect; and the parties shall negotiate
in good faith to modify the Agreement to preserve (to the extent possible) their original intent. This Agreement may be amended,
supplemented, or otherwise modified only by means of a written instrument signed by both parties.

 

	 	14.2	Independent Contractors. The parties are independent
contractors and not joint venturers or partners.

 

	 	14.3	No Security Interest. COMPANY may not encumber
or otherwise grant a security interest in any of the rights granted under this Agreement to any third party.

 

	 	14.4	Laws
                                         and Regulations. COMPANY shall comply with all local, state, federal, and international
                                         laws and regulations that are applicable to evaluating the Patent Rights or any other
                                         use of Patent Rights.

 

 

 

    Page 6 of 11

     

    

 

Agreement No. A19363

 

	 	14.5	COMPANY acknowledges that it is subject to and agrees
to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act)
controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities.
The transfer of such items may require a license from the cognizant agency of the U.S. Government or written assurances by COMPANY
that it shall not export such items to certain foreign countries
and/or foreign persons without prior approval of such agency. UFRF neither represents that a license is or is not required or
that, if required, it shall be issued.

 

Section 15 Notices
and Other Communications

 

The parties shall provide any
notice required to be given pursuant to this Agreement in writing to the addresses listed in this Section 15. Notice is effective
on the day it is delivered personally with written receipt from an authorized signatory, on the second day after the day on which
the notice has been delivered for next day delivery prepaid to a nationally recognized courier service, on the fifth business day
following deposit in the United States mail if sent certified or registered mail, (return receipt acknowledgement is not required
to certify delivery).

 

	 	If to UFRF:	 	If to COMPANY:
	 	 	 	 
	 	
        President

        University of Florida Research Foundation, Incorporated
	 	Ernesto Letiziano

                                           CEO

	 	
        223 Grinter Hall University of Florida

        P.
O. Box 115500

        Gainesville, FL 32611-5500
	 	
        Signet International Holdings, Inc.

        205 Worth Avenue, Suite
        #316

        Palm Beach, FL 33480

        Phone: (561) 832-2000

	 	 	 	Email: eletiziano@aol.com
	 	with a copy to:	 	SKYPE: NESTO. SIGNET
	 	 	 	 
	 	
        UF Innovate |
        Tech Licensing

        University of Florida
	 	 
	 	
        Attn: Director (Rm. 112)

        747 SW 2nd Avenue
	 	 
	 	Post Office Box 115575	 	 
	 	Gainesville, Florida 32611-5575	 	 

 

 

 

    Page 7 of 11

     

    

 

 

Agreement No. A19363

 

Section 16 Force Majeure

 

Neither party is responsible
for default, delay, or failure to perform, if such default, delay or failure to perform is due to causes beyond the party’s reasonable
control, including, but not limited to, strikes, lockouts, inactions of governmental authorities, war, fire, hurricane or other
natural disaster, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove those causes of
nonperformance and continues performance under this Agreement with reasonable dispatch when the causes are removed. In the event
of a default, delay or failure to perform described in this Section 16, any date or times by which either party is scheduled to
perform is extended automatically for a time equal to the time lost by reason of the excused default, delay or failure to perform.

 

Section 17 Integration

 

This Agreement
constitutes the full understanding between the parties with reference to its subject matter, and no statements or agreements
by the parties, whether oral or in writing, may modify the terms of this Agreement. Neither party may claim any amendment,
modification, or release from any provisions of this Agreement, unless the mutual agreement is in writing and signed by both
parties.

 

Section 18 Contract
Formation and Authority

 

18.1
The submission of this Agreement is not an offer, and this document is effective and binding only upon the execution by
duly authorized representatives of both COMPANY and UFRF. Copies of this Agreement that have not been executed and delivered by
both UFRF and COMPANY do not evidence an agreement between the parties. UFRF may terminate this Agreement without the requirement
of any notice to COMPANY if UFRF does not receive the Option Fee within thirty (30) days of the Effective Date.

 

18.2 UFRF and COMPANY hereby
warrant and represent that the persons signing this Agreement have authority to execute this Agreement on behalf of the party
for whom they have signed.

 

 

 

    Page 8 of 11

     

    

 

Agreement No. A19363

 

IN WITNESS WHEREOF, the parties
hereto have duly executed this Agreement on the dates indicated below.

 

	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.	 
	 	 	 
	/s/ Jim O’Connell	 	Date: 8/29/19
	 Jim O’Connell	 	 
	Assistant Vice President for Commercialization Director of Technology Licensing	 	 

 

	SIGNET INTERNATIONAL HOLDINGS, INC.	 
	 	 	 
	/s/ Ernesto Letiziano	 	Date: 8/27/19
	 Ernesto Letiziano	 	 
	CEO	 	 

 

 

 

    Page 9 of 11

     

    

 

EXHIBIT A

 

EVALUATION PLAN

 

Expected to be completed by the
company within ninety (90) days following the Effective Date.

 

 

 

    Page 10 of 11

     

    

 

EXHIBIT B

 

MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

 

CDA A19319 dated July
22, 2019 incorporated by reference.

 

 

 

 

Page 11 of 11EX-4.4

 Exhibit 4.4 

FORM OF GLOBAL NOTE 
 THIS SECURITY IS A GLOBAL
SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS
SECURITY FOR ALL PURPOSES. 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY
PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS IN WHOLE,
BUT NOT IN PART, TO NOMINEES OF THE DEPOSITORY TRUST COMPANY OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 
 HONEYWELL
INTERNATIONAL INC. 
 0.483% Senior Note Due 2022 
  

					
	REGISTERED No.	 		  	            U.S. $

 Registered CUSIP: 438516 CC8 

Registered ISIN: US438516CC86 
 HONEYWELL
INTERNATIONAL INC., a Delaware corporation (the “Company,” which term includes any successor corporation under the Indenture described herein), for value received, hereby promises to pay to CEDE & CO. or its registered assigns,
the principal sum of                              (U.S.
$             ) on August 19, 2022 (the “Maturity Date”), and to pay interest on said principal sum semiannually in arrears on February 19 and August 19 of each
year, commencing February 19, 2021 (each such date on which the Company is required to pay interest being referred to herein as an “Interest Payment Date”), at the rate of 0.483% per annum from August 19, 2020, or from the most
recent date in respect of which interest has been paid or duly provided for, until payment of said principal sum has been made or duly provided for. Notwithstanding the foregoing, if the Stated Maturity of the principal of this Note, or any Interest
Payment Date, falls on a date that is not a Business Day, the principal or interest, as the case may be, payable on such date will be payable on the next succeeding Business Day with the same force and effect as if paid on such date. The amount of
interest payable on any Interest Payment Date shall be computed on the basis of a 360-day year of twelve 30-day months. The

 
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture, be paid to the person in whose name this Note (or one or more
predecessor Notes) is registered at the close of business on February 4 or August 4 (each being referred to herein as a “Regular Record Date”), as the case may be, next preceding such Interest Payment Date. As used herein,
“Business Day” means any day, other than Saturday or Sunday, on which banks are not required or authorized by law or executive order to close in New York City. 

Payments of interest, principal and premium, if any, on this Note will be made (except as specified below) by wire transfer in same day funds
to the Registered Holder at such Holder’s address appearing on the Note Register on the relevant Regular Record Date. In the event the Notes are issued in fully certificated registered form, such payments will be made at the corporate trust
office of the Trustee in New York City, or at the option of the Company, by mailing a check to such Registered Holder. 
 Initially,
Deutsche Bank Trust Company Americas will be the Paying Agent and the Registrar (the “Note Registrar”) for this Note. The Company reserves the rights at any time to remove any Paying Agent or Note Registrar without notice, to appoint
additional or other Paying Agents and other Note Registrars without notice and to approve any change in the office through which any Paying Agent or Note Registrar acts; provided, however, that there will at all times be a Paying Agent
in New York City. 
 This Note is one of the duly authorized series (the “Series”) of debt securities of the Company (hereinafter
called the “Securities”), issued and to be issued under an indenture dated March 1, 2007, as supplemented by the First Supplemental Indenture dated as of October 27, 2017, and as further supplemented by the Second Supplemental
Indenture dated as of March 10, 2020 (collectively, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, as trustee (the “Trustee”), to which Indenture and all other indentures supplemental thereto
reference is hereby made for a statement of the rights and limitations of rights thereunder of the Holders of the Securities and of the rights, obligations and duties of the Company, the Trustee and the Paying Agent for this Note, and the terms upon
which the Securities are, and are to be, authenticated and delivered. The Securities may be issued in one or more series, which different series may be issued in various principal amounts, may mature at different times, may bear interest, if any, at
different rates, may be subject to different redemption provisions, if any, may be subject to different covenants and Events of Default and may otherwise vary as provided or permitted in the Indenture. This Note is one of the series of Securities
designated as 0.483% Senior Notes Due 2022 (herein called the “Notes”), initially limited in aggregate principal amount to $2,500,000,000. 

Each capitalized term used herein and not otherwise defined herein shall have the meaning assigned thereto in the Indenture. 

The Company may, without the consent of the Holders of the Notes, reopen this Series of Notes and issue additional notes on separate dates,
which shall form a single series and shall have 

  
 2 

 
the same terms; provided that such additional notes shall not be issued with the same CUSIP number as the Notes unless such additional notes are issued for U.S. federal income tax purposes
in a “qualified reopening” or are otherwise treated as part of the same issue for U.S. federal income tax purposes. Such further notes will be consolidated and form a single series with the Notes. 

This Note is subject to redemption, in whole or in part, at the option of the Company at any time or from time to time, upon mailed notice to
the registered address of each holder of notes to be redeemed at least 10 days but not more than 60 days prior to the redemption. Prior to August 19, 2021 (the “Par Call Date”), the “make-whole premium” redemption price will
be equal to the greater of (1) 100% of the principal amount of the notes to be redeemed and (2) the sum of the present values of the Remaining Scheduled Payments (as defined below) on such notes that would be due if such notes matured on the
Par Call Date (not including the amount, if any, of accrued and unpaid interest to, but not including, the date of redemption), discounted to the date of redemption, on a semiannual basis (assuming a 360-day
year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate (as defined below) plus 5 basis points. Accrued interest will be paid to but excluding the redemption date. 

At any time on or after the Par Call Date, the Notes are redeemable, in whole or in part, at any time and from time to time, at the
Company’s option at a redemption price equal to 100% of the principal amount of such notes to be redeemed plus accrued interest to, but not including, the redemption date. 

“Comparable Treasury Issue” means the United States Treasury security selected by a Reference Treasury Dealer (as defined below) as
having an actual or interpolated maturity comparable to the remaining term of the notes called for redemption, that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate
debt securities of comparable maturity to the remaining term of the notes called for redemption, calculated as if the maturity date of such notes were the Par Call Date. 

“Comparable Treasury Price” means, with respect to any redemption date, the average, as determined by the Company, of the Reference
Treasury Dealer Quotations (as defined below) for that redemption date. 
 “Reference Treasury Dealer” means each of Goldman
Sachs & Co. LLC, Deutsche Bank Securities Inc., Mizuho Securities USA LLC and Morgan Stanley & Co. LLC and each of their respective successors. If any one shall cease to be a primary U.S. Government securities dealer, the Company
will substitute another nationally recognized investment banking firm that is a primary U.S. Government securities dealer. 

“Reference Treasury Dealer Quotations” means, on any redemption date, the average, as determined by the Company, of the bid and
asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Company by each Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding
that redemption date. 

  
 3 

 “Remaining Scheduled Payments” means the remaining scheduled payments of principal
of and interest on the notes called for redemption that would be due after the related redemption date but for that redemption as if the maturity date of such notes were the Par Call Date. If that redemption date is not an interest payment date with
respect to the notes called for redemption, the amount of the next succeeding scheduled interest payment on such notes will be reduced by the amount of interest accrued to such redemption date. 

“Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the semiannual equivalent yield to maturity
(computed as of the third Business Day immediately preceding that redemption date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable
Treasury Price for that redemption date. 
 Any redemption may, at the Company’s discretion, be subject to one or more conditions
precedent, which will be set forth in the related notice of redemption, including, but not limited to, completion of an offering or financing or other transaction or event. In addition, if such redemption is subject to satisfaction of one or more
conditions precedent, such notice will describe each such condition, and if applicable, will state that, in the Company’s discretion, the redemption date may be delayed until such time (provided, however, that any redemption date
will not be more than 60 days after the date of the notice of redemption) as any or all such conditions will be satisfied, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions will not have
been satisfied by the redemption date, or by the redemption date as so delayed. 
 If any such condition precedent has not been satisfied,
the Company will provide written notice to the Trustee prior to the close of business one business day prior to the redemption date. Upon receipt of such notice, the notice of redemption will be rescinded or delayed, and the redemption of the notes
will be rescinded or delayed as provided in such notice. Upon receipt, the Trustee will provide such notice to each holder in the same manner in which the notice of redemption was given. 

On and after a redemption date, interest will cease to accrue on the notes called for redemption (unless the Company defaults in the payment
of the redemption price and accrued interest). 
 On or before a redemption date, the Company will deposit with a paying agent (or the
Trustee) money sufficient to pay the redemption price of and accrued interest on the notes to be redeemed on that date. If less than all of the notes are to be redeemed, the notes to be redeemed shall be selected by the Trustee in accordance with
the procedures of the Depositary Trust Company. This Note will not be subject to any sinking fund. 
 If an Event of Default with respect to
the Note shall occur and be continuing, the Trustee or the Holders of not less than 25% in principal amount of the Outstanding Notes may declare the principal of all the Notes due and payable in the manner and with the effect provided in the
Indenture. 

  
 4 

 The Indenture permits, with certain exceptions as therein provided, the amendment thereof
and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in
aggregate principal amount of the Securities at the time Outstanding of each series to be affected thereby (voting as a class). The Indenture also contains provisions permitting the Holders of a majority in aggregate principal amount of the
Securities of each series to be affected at the time Outstanding, on behalf of the Holders of all Securities of each such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the
Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in
exchange hereof or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note. 
 Except as provided below in
the case of a defeasance, no reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest on this
Note at the times, place and rate, and in the coin or currency, herein and in the Indenture prescribed. 
 Under the terms of the Indenture,
the Company may satisfy and discharge its obligations with respect to the Notes by depositing in trust for the Holders of the Outstanding Notes an amount in cash or the equivalent in securities of the government which issued the currency in which
the Notes are denominated or government agencies backed by the full faith and credit of such government sufficient to pay and discharge the entire indebtedness on the Notes for principal of and premium, if any, and interest then due or to become due
to the Stated Maturity of the principal of the Notes (a “defeasance”). In such event, a Company will be released and discharged from its obligations to pay interest on the Notes and to pay the principal thereof at its Maturity. 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Note may be registered on the Note
Register of the Company upon surrender of this Note for registration of transfer at the office or agency of the Company in New York City duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the
Note Registrar duly executed by, the Holder hereof or by his attorney duly authorized in writing, and thereupon one or more new Notes in registered form, of authorized denominations and for the same aggregate principal amount, will be issued in the
name or names of the designated transferee or transferees and delivered at the office of the Note Registrar in New York City, or mailed, at the request, risk and expense of such transferee or transferees, to the address or addresses shown in the
Note Register for such transferee or transferees. 
 Prior to due presentment of this Note for registration of transfer, the Company, the
Trustee, the Note Registrar and any agent of the Company, the Trustee or the Note Registrar may treat the person in whose name this Note is registered as the owner hereof for all purposes, whether or not this Note is overdue, and neither the
Company, the Trustee, the Note Registrar nor any such agent shall be affected by notice to the contrary. 

  
 5 

 This Note is issuable only in fully registered form, without coupons, in minimum
denominations of $2,000 and any integral multiple of $1,000 in excess thereof. 
 No service charge will be made for a transfer or exchange
of the Notes, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

This Note (the “Global Note”) is a Global Security as referred to in the Indenture and is not exchangeable for one or more
certificated Notes; provided, however, that if at any time the Depository notifies the Company that it is unwilling or unable to continue as Depository or if at any time the Depository shall no longer be eligible or in good standing under the
Securities Exchange Act of 1934, as amended, or any other applicable statute or regulation, the Company shall appoint a successor Depository. If a successor Depository is not appointed by the Company within 90 days after the Company receives such
notice or becomes aware of such ineligibility, the Company will execute, and the Trustee or its agent, upon receipt of a Corporation Order for the authentication and delivery of individual Notes of this series in exchange for this Global Note, will
authenticate and deliver, individual Notes of this series in an aggregate principal amount equal to the principal amount of this Global Note in exchange for this Global Note. 

In addition, the Company may at any time and in its sole discretion determine that the Notes represented by this Global Note shall no longer
be represented by this Global Note. In such event the Company will execute, and the Trustee or its agent, upon receipt of a Corporation Order for the authentication and delivery of individual Notes of this series in exchange for this Global Note,
will authenticate and deliver, individual Notes of this series in an aggregate principal amount equal to the principal amount of this Global Note in exchange for this Global Note. 

This Note and all the obligations of the Company hereunder are direct, senior unsecured and unsubordinated obligations of the Company and rank
pari passu with all other senior unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 

This Note shall be construed in accordance with and governed by the laws of the State of New York. 

Unless the certificate of authentication hereon has been manually executed by or on behalf of the Trustee under the Indenture, this Note shall
not be entitled to any benefits under the Indenture or be valid or obligatory for any purpose. 

  
 6 

 IN WITNESS WHEREOF, HONEYWELL INTERNATIONAL INC. has caused this Note to be manually
executed. 
 Dated: August 19, 2020 

 

			
	HONEYWELL INTERNATIONAL INC.
		
	By:	 	  

	Name:	 	James E. Colby
	Title:	 	Vice President and Treasurer

  

			
	ATTEST:
		
	By:	 	  

	Name:	 	Su Ping Lu
	Title:	 	Deputy Corporate Secretary

  
 [Signature Page –
Global Note] 

 ABBREVIATIONS 

The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they were written out
in full according to applicable laws or regulations. 
 TEN COM–as tenants in common 

 

							
	UNIF GIFT MIN ACT–
                                         
                           	 	Custodian                                  
                                         
                                         
    

 Under Uniform Gifts to Minors Act 

 
  

 
 TEN ENT–as tenants
by the entireties 
 JT TEN–as joint tenants with right of survivorship and not as tenants in common 

Additional abbreviations may also be used though not in the above list. 

FOR THE VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfer(s) unto 

 

	
	 Please Insert Social Security or Other

Identifying Number of Assignee:

	  

	  

  
  

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS 

INCLUDING ZIP CODE OF ASSIGNEE: 
  

 
  

 
  

 
 the within Note and all rights thereunder, hereby
irrevocably constituting and appointing                      attorney to transfer said Note on the books of the Company, with full power of
substitution in the premises. 
 Dated:
                                         
            
 NOTICE: The signature to this assignment must correspond with the name as written
upon the face of the within instrument in every particular, without alteration or enlargement, or any change whatever. 

 Unless the certificate of authentication hereon has been executed by the Trustee referred to
on the reverse hereof by manual signature of one of its authorized signatories, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose 

 

							
	Dated: August 19, 2020	 	        	 	CERTIFICATE OF AUTHENTICATION
			
		 		 	This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture.
			
		 		 	Deutsche Bank Trust Company Americas, as Trustee

  

							
				
		 		 	By:	 	  

		 		 	Name:	 	
		 		 	Title:	 	

  
 [Signature Page –
Global Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]